Today were reported iShares NASDAQ Biotechnology Index (ETF)’s daily net flows. The ETF registered $-104.13M asset outflows for -1.30% decrease, reaching $7884.29M after yestarday’s trading session. The chart of iShares NASDAQ Biotechnology Index (ETF) shows negative short-term setup. In the net flows calculation is not included the performance of the etf but only share redemptions (outflows) and share purchases (inflows). Net outflows leads to less cash for managers to invest, which theoretically decreases demand for the etf’s holdings. The ETF decreased 3.12% or $9.21 during the last trading session, hitting $285.87. About 40 shares traded hands. iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) has risen 9.32% since February 26, 2016 and is uptrending. It has underperformed by 1.10% the S&P500.
The ETF’s YTD performance is -16.87%, the 1 year is -17.76% and the 3 year is 13.3%.
The ETF’s average P/E ratio is 19.53, the price to book is 3.63, the price to sales is 5.21 and the price to cashflow is 10.38. iShares NASDAQ Biotechnology Index (ETF) is in the ETF category: , is part of the fund family and currently has $ net assets. It was started on 1/1/0001. The fund’s top holdings are: Amgen Inc. for 8.49% of assets, Biogen Inc. for 8.32%, Celgene Corporation for 7.97%, Gilead Sciences Inc. for 7.10%, Regeneron Pharmaceuticals Inc. for 7.01%, Illumina Inc. for 4.46%, Vertex Pharmaceuticals Incorpor for 4.00%, Mylan N.V. for 3.85%, Alexion Pharmaceuticals Inc. for 3.29%, Shire PLC ADR for 2.98%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as 0% yield.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.